Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 12/20 | 0.35 |
| ▸ | MMP8 | P22894 | 10/20 | 0.35 |
| ▸ | MMP2 | P08253 | 11/20 | 0.34 |
| ▸ | MMP3 | P08254 | 10/20 | 0.34 |
| ▸ | MMP13 | P45452 | 8/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945324 | 0.91 | ADAM17 (0.37) | ADAM17TSHR | |
| SCHEMBL6947013 | 0.81 | MMP1 (0.52) | ADAM17MMP1MMP8MMP2MMP3 | |
| SCHEMBL6947526 | 0.73 | ADAM17 (0.47) | ADAM17MMP1MMP8MMP2MMP3 | |
| SCHEMBL6940034 | 0.67 | ADAM17 (0.52) | ADAM17MMP1MMP8MMP2MMP3 | |
| SCHEMBL8098302 | 0.66 | ADAM17 (0.66) | ADAM17MMP1MMP8MMP2MMP3 | |
| SCHEMBL6938052 | 0.66 | ADAM17 (0.66) | ADAM17MMP1MMP8MMP2MMP3 | |
| SCHEMBL6940005 | 0.66 | ADAM17 (0.41) | ADAM17MMP2MMP13MMP14 | |
| SCHEMBL7928825 | 0.64 | ADAM17 (0.37) | ADAM17MMP1MMP8 | |
| SCHEMBL8114301 | 0.64 | MMP1 (0.33) | ADAM17MMP1MMP8MMP2MMP3 | |
| SCHEMBL6945579 | 0.63 | ADAM17 (0.62) | ADAM17MMP1MMP8MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993442-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6235787-B1 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; BONE DISORDERS; SKIN DISORDERS; MULTIPLE SCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-05-22 | — | — | US | disclosed |